PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
News|Articles|March 5, 2026
- Vol.27/No.5
- Volume 27
- Issue 05
Rising Incidence, Unclear Drivers: Knowledge Gaps Persist in Early-Onset CRC
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty , Kirsty Mackay
John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer (CRC) during CRC Awareness Month.
Advertisement
Advertisement
Colorectal cancer (CRC) incidence among adults younger than 50 years has nearly doubled since the 1990s, transforming what was once a projected trend into a present-day clinical crisis.1 By 2030, CRC is projected to increase in incidence by 90%, and recent data show that the disease is already the leading cause of cancer-related death among men and women younger than 50 years.1,2
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.
Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.
The CDH17-targeting antibody-drug conjugate received the designation for previously treated advanced unresectable or metastatic colorectal cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Premal H. Thaker, MD, MS, discusses INCB123667 in ovarian cancer and the ongoing MAESTRA 2 study.
Advertisement
Advertisement